Active Ingredient(s):Daratumumab + Hyaluronidase-fihj FDA Approved: * May 1, 2020 Pharm Company: *JANSSEN BIOTECH Category:Cancer
Daratumumab/hyaluronidase, sold under the brand name Darzalex Faspro, is a fixed-dose combination medication for the treatment of adults with newly diagnosed or relapsed/refractory multiple myeloma. It is a combination of daratumumab and hyaluronidase. It is administered via subcutaneous injection.
The most common adverse reaction using daratumumab/hyaluronidase as monotherapy is upper respiratory t...
* May have multiple approval dates, manufacturers, or labelers.